Nyrada Inc. (ASX:NYR) Progresses Phase I Clinical Trial
Nyrada Inc. (ASX:NYR) advances its Phase I clinical trial to the second cohort, anticipating final readouts in Q3 CY2025.

Nyrada Inc. (ASX:NYR) advances its Phase I clinical trial to the second cohort, anticipating final readouts in Q3 CY2025.
Atomo Diagnostics (ASX:AT1) scales national HIV self-test program in Australia and expands into New Zealand through Chemist Warehouse.
Mesoblast (ASX:MSB) announces its allogeneic cell therapies are exempt from U.S. tariffs as ‘U.S. Country of Origin’ products.
Orthocell (ASX:OCC) secures FDA clearance for Remplir™, enabling entry into the US $1.6 billion nerve repair market.
Echo IQ (ASX:EIQ) partners with Mayo Clinic Platform to advance EchoSolv HF and progress towards FDA clearance for its heart failure solution.
Cann Group Limited (ASX:CAN) signs supply agreements with Queensland’s Chemist Warehouse outlets to distribute its medicinal cannabis products.
Race Oncology (ASX:RAC) initiates its first Australian clinical site for the Phase 1 RC220 trial, marking a significant step in advancing cancer treatment.
Bioxyne Limited (ASX:BXN) secures a $7 million manufacturing agreement with NectarTek, significantly increasing FY2026 revenue projections.
Biome Australia Limited (ASX:BIO) secures a $5.0 million debt facility with NAB to drive growth and enhance financial stability.
Epsilon Healthcare Limited (ASX:EPN) enters voluntary administration, resulting in leadership changes and subdued operations.